Giskeødegård Guro F, Madssen Torfinn S, Euceda Leslie R, Tessem May-Britt, Moestue Siver A, Bathen Tone F
Department of Circulation and Medical Imaging, Norwegian University of Science and Technology-NTNU, Trondheim, Norway.
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology-NTNU, Trondheim, Norway.
NMR Biomed. 2018 Apr 19:e3927. doi: 10.1002/nbm.3927.
This review describes the current status of NMR-based metabolomics of biofluids with respect to cancer risk assessment, detection, disease characterization, prognosis, and treatment monitoring. While the metabolism of cancer cells is altered compared with that of non-proliferating cells, the metabolome of blood and urine reflects the entire organism. We conclude that many studies show impressive associations between biofluid metabolomics and cancer progression, but translation to clinical practice is currently hindered by lack of validation, difficulties in biological interpretation, and non-standardized analytical procedures.
本综述描述了基于核磁共振的生物流体代谢组学在癌症风险评估、检测、疾病特征描述、预后及治疗监测方面的现状。与非增殖细胞相比，癌细胞的代谢发生了改变，而血液和尿液的代谢组反映了整个机体的情况。我们得出结论，许多研究表明生物流体代谢组学与癌症进展之间存在令人瞩目的关联，但目前由于缺乏验证、生物学解释困难以及分析程序不标准化，向临床实践的转化受到了阻碍。
